Aurobindo Pharma announced that CuraTeQ Biologics, a fully owned subsidiary, intends to spend about Rs 300 crore to increase the capacity of biologics manufacturing facilities.
Aurobindo Pharma stated in a regulatory filing that the board of directors of CuraTeQ Biologics Pvt Ltd approved the expansion of its operations by building a second, larger-capacity mammalian cell culture manufacturing facility to fulfil future requirements.
“The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore,” it said, adding that the facility is likely to be fully operational by FY26.
